Based on findings of a randomized trial, the nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and the anti-PD-L1 atezolizumab have now entered the therapeutic landscape of breast cancer and are currently available for use in daily clinical practice. This evidence concerns the gene CD274 and breast cancer.